Earliest Clinical Manifestations and Natural History of Neurofibromatosis Type 2 (NF2) in Childhood: A Study of 24 Patients[*]

Abstract

Background: Neurofibromatosis type 2 (NF2) is an autosomal dominant disease characterised by the development of multiple nervous system tumours, ocular abnormalities, and skin tumours. Although classically considered a disease of adults, initial signs and/or symptoms may be evident in childhood and are often unrecognised. Objectives: The aim of this study was to identify the earliest clinical presentations of NF2 and to characterise the clinical course and outcome in children with NF2. Methods: We have performed a retrospective (years 1990 - 1998) and prospective (years 1998 - 2004) study of 24 patients (10 males, 14 females; currently aged 4 to 22 years) fulfilling the revised (Manchester) NF2 criteria seen at the Universities of Catania and Rome, Italy. Results: Causes of referral prior to a definitive diagnosis of NF2 were: 1) Ophthalmologic problems: early onset lens opacities (n = 3); strabismus (n = 3) and amblyopia (n = 3) (due to underlying cranial nerves and/or brain tumours); 2) Otolaryngology problems: hearing loss and tinnitus (n = 2) in early teens disregarded or treated as ear infections; hoarse (n = 1) or bitonal (n = 1) voice; 3) Neurological dysfunction: seizures secondary to intracranial meningioma (n = 1) or vestibular schwannomas (VS) (n = 1), neurological dysfunction related to brainstem and/or spinal cord tumours (n = 7), isolated and multiple cranial nerve deficits (n = 10), and peripheral neuropathy secondary to schwannomas (n = 4); 4) Skin manifestations: schwannomas misdiagnosed as neurofibromas because of associated café-au-lait spots (n = 2); café-au-lait spots (n = 8) and skin tumours (n = 3). A family history was relevant in 20 % of the patients. Molecular genetic analysis of the NF2 gene revealed typical truncating mutations in all the 5 familial cases and in 2/10 sporadic cases analysed. Conclusions: Children with NF2 often first come to medical attention because of ocular, subtle skin, or neurological problems the significance of which is realised when they later present with more classical symptoms due to bilateral VS or other intracranial tumours. The clinical course at this young age is highly variable, depending on tumour burden, early surgical intervention, surgical outcome after tumour resection, and complications.

Key words

Neurofibromatosis - NF2 - early onset - paediatric

1 This work was done at the Departments of Pediatrics, University of Catania and Division of Child Neurology, Department of Pediatrics, University of Rome “La Sapienza”, Italy. Presented in part at the 5th European Pediatric Neurology Society (EPNS) Meeting held in Taormina, Italy, 22 - 25 October 2003 (Eur J Pediatr Neurol 2003; 7: 359)

References

• 1 Baser M E, Friedman J M, Wallace A J, Ramsden R T, Joe H, Evans D G. et al . Evaluation of clinical diagnostic criteria for neurofibromatosis 2.  Neurology. 2002;  59 1759-1765
• 2 Baser M E, Evans D GR, Gutmann D H. Neurofibromatosis 2.  Curr Opin Neurol. 2003;  16 27-33
• 3 Evans D G, Huson S M, Donnai D, Neary W, Blair V, Newton W. et al . A clinical study of type 2 neurofibromatosis.  Q J Med J. 1992;  304 603-618
• 4 Evans D G, Huson S M, Donnai D, Neary W, Blair V, Teare D. et al . A genetic study of type 2 neurofibromatosis in the United Kingdom. I: Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity.  J Med Genet. 1992;  29 841-846
• 5 Evans D GR, Trueman L, Wallace A, Collins S, Strachan T. Genotype/phenotype correlation in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations.  J Med Genet. 1998;  35 450-455
• 6 Evans D GR, Birch J M, Ramsden R T. Paediatric presentation of type 2 neurofibromatosis.  Arch Dis Child. 1999;  81 496-499
• 7 Evans D GE, Sainio M, Baser M E. Neurofibromatosis type 2.  J Med Genet. 2000;  37 897-904
• 8 Friedman J, Gutmann D H, MacCollin M, Riccardi V M. Neurofibromatosis: Phenotype, Natural History and Pathogenesis. 3rd ed. Baltimore, London; Johns Hopkins University Press 1999
• 9 Gutmann D H, Aylsworth A, Carey J C, Korf B, Marks J, Pyeritz R E. et al . The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2.  JAMA. 1997;  278 51-53
• 10 Health supervision for children with neurofibromatosis . American Academy of Pediatrics Committee on Genetics.  Pediatrics. 1995;  92 368-372
• 11 Huson S M, Hughes R AC. The Neurofibromatoses. A Pathogenetic and Clinical Overview. London; Churchill Livingstone 1994
• 12 Huson S M, Ruggieri M. The neurofibromatoses. Harper J, Oranje JM, Rose M Pediatric Dermatology. Oxford; Blackwell Science 2000: 1204-1224
• 13 MacCollin M, Bove C, Kluwe L, Ojemann R, Mautner V F. The natural history of neurofibromatosis 2 in 31 affected children.  Ann Neurol. 1996;  44 A576
• 14 MacCollin M, Mautner V F. The diagnosis and management of neurofibromatosis type 2 in childhood.  Semin Pediatr Neurol. 1998;  5 243-252
• 15 Mautner V F, Tatagiba M, Guthoff R, Samili M, Pulst S M. Neurofibromatosis type 2 in the paediatric age group.  Neurosurgery. 1993;  33 92-96
• 16 Mautner V F, Baser M E, Takkar S D, Feigen U M, Friedman J M, Kluwe L. Vestibular schwannoma growth in patients with neurofibromatosis type 2: a longitudinal study.  J Neurosurg. 2002;  96 223-228
• 17 Mautner V F, Lindenau M, Baser M E, Kluwe L, Gottschalk J. Skin abnormalities in neurofibromatosis type 2.  Arch Dermatol. 1997;  133 1539-1543
• 18 National Institutes of Health Consensus Development Conference Statement . Neurofibromatosis.  Arch Neurol. 1988;  45 575-578
• 19 National Institutes of Health Consensus Development Conference Statement . Acoustic neuromas.  Arch Neurol. 1994;  51 201-207
• 20 Nunes F, MacCollin M. Neurofibromatosis type 1 in the pediatric population.  J Child Neurol. 2002;  18 718-724
• 21 Parry D M, Eldridge R, Kaiser-Kupfer M I, Bouzas E A, Pikus A, Patronas N. Neurofibromatosis type 2 (NF2): Clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity.  Am J Med Genet. 1994;  52 450-461
• 22 Pediatric Committee . Pediatric audiologic profile in type 1 and type 2 neurofibromatosis.  J Am Acad Audiol. 1995;  6 54-62
• 23 Ragge N K, Baser M E, Klein J, Nchiparul A, Sainza J, Pulst J M. et al . Ocular abnormalities in neurofibromatosis 2.  Am J Ophthalmol. 1995;  120 634-641
• 24 Ruggieri M. The different forms of neurofibromatosis.  Child's Nerv Syst. 1999;  15 295-308
• 25 Ruggieri M, Huson S M. Clinical presentations of neurofibromatosis type 2 in childhood.  Eur J Pediatr Neurol. 1999;  3 A66
• 26 Ruggieri M, Huson S. The clinical and diagnostic implications of mosaicism in the neurofibromatosis.  Neurology. 2001;  56 1433-1443

1 This work was done at the Departments of Pediatrics, University of Catania and Division of Child Neurology, Department of Pediatrics, University of Rome “La Sapienza”, Italy. Presented in part at the 5th European Pediatric Neurology Society (EPNS) Meeting held in Taormina, Italy, 22 - 25 October 2003 (Eur J Pediatr Neurol 2003; 7: 359)